Mulder, G
Garg called the current data quite variable. For every study that says, yes, there's a problem, there are other studies that suggest maybe there's no problem or there may be some benefit to the drugs, he says
In the SURPASS-2 study, tirzepatide 15 mg resulted in a faster and greater decline in body weight ( 5.5 kg) compared to semaglutide 1.0 mg, more than doubling the proportion of patients achieving at least 10% weight loss (57% vs 24%) [3]
Weight loss reduces systemic inflammation, improves metabolic hormone balance, and may restore healthier sleep patternsall factors that influence brain chemistry and emotional regulation
The next drug on fast track at FDA to be imminently approved is tirzepatide (Mounjaro) following its approval for diabetes in May 2022
Instead of filling out an online form, youll have an in-person consultation with Dr